Frossard N, Benabdesselam O, Purohit A, Mounedji N, Pauli G
INSERM U425, neuroimmunopharmacologie pulmonaire, faculté de pharmacie, Illkirch, France.
Fundam Clin Pharmacol. 2000 Jul-Aug;14(4):409-13. doi: 10.1111/j.1472-8206.2000.tb00423.x.
We have compared the inhibitory effects of ebastine (10 mg), ebastine (20 mg) and cetirizine (10 mg) on histamine-induced wheal and flare skin reactions 24 h following a 6-day-long treatment. This was a double-blind, randomised, crossover, placebo-controlled study involving 24 healthy volunteers (18-65 years) with negative skin prick tests and the absence of specific IgEs to common allergens. Subjects were randomised to receive each of the following treatments once daily for 6 days: ebastine (10 mg), ebastine (20 mg), cetirizine (10 mg) or placebo with a washout period of 5 days. Twenty-four hours after the last dose of each treatment, histamine skin prick tests were performed (0, 0.5, 1, 2.5, 5, 10, 20, 50, 100 and 200 mg/mL), and wheal and flare responses were measured. All active treatments produced significant inhibition of the wheal responses compared to placebo (P < 0.001). Wheal response inhibition was significantly better with 20 mg of ebastine compared with 10 mg of ebastine and 10 mg of cetirizine. In a comparison to histamine concentrations required to produce a wheal surface area of 10 mm2, 20 mg of ebastine was also significantly better than ebastine 10 mg and cetirizine (P < 0.001), and 10 mg ebastine was significantly better than cetirizine (P < 0.05). Highly significant (P < 0.001) effects on the flare response were observed with each active treatment compared to placebo, with no difference between groups. The frequency of adverse events, primarily somnolence, was similar among the four treatment groups. Our results clearly indicate that ebastine, at either recommended dosage of 10 and 20 mg, and cetirizine produced significant inhibition of the histamine-induced wheal and flare reaction compared to placebo for up to 24 h. A superior efficacy of 20 mg of ebastine is observed compared with 10 mg of ebastine and 10 mg of cetirizine on the skin wheal response 24 h after the last dose of a 6-day-long treatment. This study clearly proves ebastine to be an effective, truly once-daily antihistamine.
我们比较了依巴斯汀(10毫克)、依巴斯汀(20毫克)和西替利嗪(10毫克)在为期6天的治疗后24小时对组胺诱导的风团和潮红皮肤反应的抑制作用。这是一项双盲、随机、交叉、安慰剂对照研究,涉及24名健康志愿者(18 - 65岁),他们的皮肤点刺试验为阴性,且对常见变应原不存在特异性IgE。受试者被随机分组,每天接受以下每种治疗一次,共6天:依巴斯汀(10毫克)、依巴斯汀(20毫克)、西替利嗪(10毫克)或安慰剂,洗脱期为5天。在每种治疗的最后一剂给药24小时后,进行组胺皮肤点刺试验(0、0.5、1、2.5、5、10、20、50、100和200毫克/毫升),并测量风团和潮红反应。与安慰剂相比,所有活性治疗均对风团反应产生显著抑制(P < 0.001)。与10毫克依巴斯汀和10毫克西替利嗪相比,20毫克依巴斯汀对风团反应的抑制效果显著更好。与产生10平方毫米风团表面积所需的组胺浓度相比,20毫克依巴斯汀也显著优于10毫克依巴斯汀和西替利嗪(P < 0.001),且10毫克依巴斯汀显著优于西替利嗪(P < 0.05)。与安慰剂相比,每种活性治疗对潮红反应均观察到高度显著(P < 0.001)的效果,各治疗组之间无差异。四个治疗组中不良事件的发生率,主要是嗜睡,相似。我们的结果清楚地表明,与安慰剂相比,依巴斯汀10毫克和20毫克的推荐剂量以及西替利嗪在长达24小时内均对组胺诱导的风团和潮红反应产生显著抑制。在为期6天的治疗的最后一剂给药24小时后,观察到20毫克依巴斯汀在皮肤风团反应上的疗效优于10毫克依巴斯汀和10毫克西替利嗪。这项研究清楚地证明依巴斯汀是一种有效的、真正每日一次的抗组胺药。